ERBB2 and breast cancer: HER2 + BC-LMD patients receiving IT therapy had an improved median OS by 11.1 months when compared to HER2 + BC-LMD patients that did not receive IT therapy (Additional file 2: Fig. S5D, p < 0.0001).